Spots Global Cancer Trial Database for Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

Official Title: Pulmonary Function Tests (PFT) in a Phase I Patient Population

Study ID: NCT00914147

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

pulmonary function testing

Study Description

Brief Summary: RATIONALE: Measuring how well the lungs work in patients with cancer may help doctors predict how patients will respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying lung function testing in patients with locally advanced or metastatic solid tumors.

Detailed Description: OBJECTIVES: Primary * To obtain the distribution of DLCO, FVC, and FEV_1 by pulmonary function testing (PFT) in patients with heavily pretreated locally advanced or metastatic solid tumors referred to the Karmanos Cancer Institute (KCI) Phase I Clinical Trials Program. * To estimate the mean DLCO to within 4 units (% of predicted) of the true mean with 95% confidence. Secondary * To estimate the percentage of patients who meet the defined eligibility criteria (including PFT levels, especially DLCO) from the entire population enrolled in the KCI Phase I Clinical Trials Program. OUTLINE: Patients undergo pulmonary function testing comprising spirometry test, lung volumes, and DLCO measurement utilizing the single-breath breath-holding technique. Patients then proceed to treatment on a phase I clinical trial.